Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer - PubMed
5 hours ago
- #immunotherapy
- #antibody-drug conjugates
- #triple-negative breast cancer
- Triple-negative breast cancer (TNBC) is challenging to treat due to its aggressive nature and lack of ER, PR, and HER2 expression.
- Antibody-drug conjugates (ADCs) like sacituzumab govitecan and datopotamab deruxtecan show superior efficacy over standard chemotherapy in metastatic TNBC.
- Combining ADCs with immune checkpoint inhibitors enhances antitumor activity, supported by trials such as MORPHEUS-panBC and BEGONIA.
- These novel combinations are being evaluated in neoadjuvant and adjuvant settings, expanding beyond metastatic disease.
- The article summarizes recent advances, discusses synergistic mechanisms, and explores future personalized therapeutic strategies for TNBC.